The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience

We aimed to analyze response rates, survival, and factors influencing outcomes in patients with ovarian germ cell tumors undergoing HDC and ASCT. Twenty-one patients were included. After HDC + ASCT, CR was observed in 11 patients (52.3%), PR in 3 patients (14.3%). Median PFS and OS were calculated to be 6.0 months and 14.8 months, respectively. Salvage HDC + ASCT is an effective option in ovarian germ cell tumours. Objective: We aimed to investigate response rates, survival analyses and factors affecting survival in patients with relapsed or refractory ovarian germ cell tumours who had previously received multiple lines of treatment, including high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Methods: This study was designed as a cross-sectional, retrospective study. Results: Twenty-one patients were included. After HDC + ASCT, complete response (CR) was observed in 11 patients (52.3%), partial response (PR) in 3 patients (14.3%), stable disease (SD) in 3 patients (14.3%) and progressive disease (PD) in 4 patients (19.1%). TRM was observed in 1 patient. Median followup was 51.7 months. Median PFS and OS after HDC + ASCT were calculated to be 6.0 months and 14.8 months, respectively. Conclusions: Salvage HDC + ASCT is an effective option in the treatment of relapsed/refractory ovarian germ cell tumours, offering the potential for prolonged survival and cure.